These cases demonstrate the potential of Pazopanib as a promising therapeutic option for patients with <i>EWSR1::CREM</i> fusion-positive soft tissue sarcomas, including metastatic undifferentiated round cell sarcomas. The gene discussed is EWSR1; the disease is soft tissue sarcoma.